Sign up to save your podcasts
Or
Share IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option episodes
- IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
17 min
About IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
From the publisher's feed
Listeners can expect to learn about:
• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
• The current IgAN treatment landscape
• The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial